Vaccination potential will not be achieved without increased production, affordable pricing, global availability, and successful rollout.

[2greys]

The COVID-19 pandemic has caused substantial excess mortality and plunged national economies into deep recessions.1

Although the spread of the virus can be mitigated through physical distancing, face coverings, and testing and tracing—and potentially with therapeutics—the risk of outbreaks and disruption to economic and social life will probably remain until effective vaccines are administered to large portions of the global population to prevent hospitalisation and severe disease, and preferably achieve herd immunity to halt transmission of the virus.

Several COVID-19 vaccines have now been authorised or approved for human use, with many more in the late stages of clinical development. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities (figure 1). These four dimensions of the global vaccination challenge are closely related, and the development and production steps have important implications for pricing, allocation, and public confidence.

thelancet.com/journals/lanc...

[Badbessie]

The Governments new super vaccine factory which hopefully will be up and running by the end of the year will greatly improve both the UKs and the world's ability to get doses.